Advertisement

Long-term Safety of Fecal Microbiota Transplantation for Recurrent Clostridioides difficile Infection

Published:January 10, 2021DOI:https://doi.org/10.1053/j.gastro.2021.01.010

      Background

      Fecal microbiota transplantation (FMT) is highly effective for treating recurrent Clostridioides difficile infection (CDI), with emerging data on intermediate and long-term safety.

      Methods

      A prospective survey-based study was conducted (September 2012–June 2018) in patients undergoing FMT for recurrent CDI. Data on demographics and comorbidities were abstracted from medical records. Patients were contacted at 1 week, 1 month, 6 months, 1 year (short-term), and ≥2 years post-FMT (long-term). Symptoms and new medical diagnoses were recorded at each time point. Data were weighted to account for survey nonresponse bias. Multivariate logistic regression models for adverse events were built using age (per 10-year increment), sex, time of survey, and comorbidities. P < .05 was considered statistically significant.

      Results

      Overall, 609 patients underwent FMT; median age was 56 years (range, 18–94), 64.8% were women, 22.8% had inflammatory bowel disease (IBD). At short-term follow-up (n = 609), >60% of patients had diarrhea and 19%-33% had constipation. At 1 year, 9.5% reported additional CDI episodes. On multivariable analysis, patients with IBD, dialysis-dependent kidney disease, and multiple FMTs had higher risk of diarrhea; risk of constipation was higher in women and lower in IBD (all P < .05). For long-term follow-up (n = 447), median time of follow-up was 3.7 years (range, 2.0–6.8). Overall, 73 new diagnoses were reported: 13% gastrointestinal, 10% weight gain, 11.8% new infections (all deemed unrelated to FMT). Median time to infections was 29 months (range, 0–73) post-FMT.

      Conclusion

      FMT appears safe with low risk of transmission of infections. Several new diagnoses were reported, which should be explored in future studies.

      Keywords

      Abbreviations used in this paper:

      AE (adverse event), CDI (Clostridioides difficile infection), FMT (fecal microbiota transplantation), GI (gastrointestinal), IBD (inflammatory bowel disease), IBS (irritable bowel syndrome), IBS-C (irritable bowel syndrome constipation-predominant), IBS-D (irritable bowel syndrome diarrhea-predominant), IBS-M (irritable bowel syndrome-mixed)
      To read this article in full you will need to make a payment
      AGA Member Login
      Login with your AGA username and password.
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • McDonald L.C.
        • Gerding D.N.
        • Johnson S.
        • et al.
        Clinical practice guidelines for Clostridium difficile infection in adults and children: 2017 update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA).
        Clin Infect Dis. 2018; 66: e1-e48
        • Bajaj J.S.
        • Kassam Z.
        • Fagan A.
        • et al.
        Fecal microbiota transplant from a rational stool donor improves hepatic encephalopathy: a randomized clinical trial.
        Hepatology. 2017; 66: 1727-1738
        • Johnsen P.H.
        • Hilpüsch F.
        • Cavanagh J.P.
        • et al.
        Faecal microbiota transplantation versus placebo for moderate-to-severe irritable bowel syndrome: a double-blind, randomised, placebo-controlled, parallel-group, single-centre trial.
        Lancet Gastroenterol Hepatol. 2018; 3: 17-24
        • Moayyedi P.
        • Surette M.G.
        • Kim P.T.
        • et al.
        Fecal microbiota transplantation induces remission in patients with active ulcerative colitis in a randomized controlled trial.
        Gastroenterology. 2015; 149: 102-109.e6
      1. Food and Drug Administration. Fecal microbiota for transplantation: safety communication- risk of serious adverse reactions due to transmission of multi-drug resistant organisms. 2019. Available at: https://www.fda.gov/safety/medical-product-safety-information/fecal-microbiota-transplantation-safety-communication-risk-serious-adverse-reactions-due.

      2. Food and Drug Administration. Fecal microbiota for transplantation: safety alert - risk of serious adverse events likely due to transmission of pathogenic organisms. 2020. Available at: https://www.fda.gov/safety/medical-product-safety-information/fecal-microbiota-transplantation-safety-communication-risk-serious-adverse-reactions-due.

        • DeFilipp Z.
        • Bloom P.P.
        • Torres Soto M.
        • et al.
        Drug-resistant E. coli bacteremia transmitted by fecal microbiota transplant.
        N Engl J Med. 2019; 381: 2043-2050
        • Brandt L.J.
        • Aroniadis O.C.
        • Mellow M.
        • et al.
        Long-term follow-up of colonoscopic fecal microbiota transplant for recurrent Clostridium difficile infection.
        American Journal of Gastroenterology. 2012; 107: 1079-1087
        • Jalanka J.
        • Hillamaa A.
        • Satokari R.
        • et al.
        The long-term effects of faecal microbiota transplantation for gastrointestinal symptoms and general health in patients with recurrent Clostridium difficile infection.
        Aliment Pharmacol Ther. 2018; 47: 371-379
        • Mamo Y.
        • Woodworth M.H.
        • Wang T.
        • et al.
        Durability and long-term clinical outcomes of fecal microbiota transplant treatment in patients with recurrent Clostridium difficile infection.
        Clin Infect Dis. 2018; 66: 1705-1711
        • Perler B.K.
        • Chen B.
        • Phelps E.
        • et al.
        Long-term efficacy and safety of fecal microbiota transplantation for treatment of recurrent Clostridioides difficile infection.
        J Clin Gastroenterol. 2020; 54: 701-706
        • Kelly C.R.
        • Yen E.F.
        • Grinspan A.M.
        • et al.
        Fecal microbiota transplant is highly effective in real-world practice: initial results from the FMT National Registry.
        Gastroenterology. 2021; 160: 183-192.e3
        • Tariq R.
        • Weatherly R.
        • Kammer P.
        • et al.
        Donor screening experience for fecal microbiota transplantation in patients with recurrent C. difficile infection.
        J Clin Gastroenterol. 2018; 52: 146-150
        • Tariq R.
        • Weatherly R.M.
        • Kammer P.P.
        • et al.
        Experience and outcomes at a specialized Clostridium difficile clinical practice.
        Mayo Clin Proc Innov Qual Outcomes. 2017; 1: 49-56
        • Palsson O.S.
        • Whitehead W.E.
        • van Tilburg M.A.L.
        • et al.
        Development and validation of the Rome IV Diagnostic Questionnaire for Adults.
        Gastroenterology. 2016; 150: 1481-1491
        • Alang N.
        • Kelly C.R.
        Weight gain after fecal microbiota transplantation.
        Open Forum Infect Dis. 2015; 2: ofv004
        • Khanna S.
        • Kraft C.S.
        Fecal microbiota transplantation: tales of caution [published online ahead of print September 29, 2020]. Clin Infect Dis.
        • Zellmer C.S.M.
        • Huntley M.H.
        • Osman M.
        • Olesen S.W.
        • Ramakrishna B.
        Shiga toxin-producing E. coli transmission via fecal microbiota transplant [published online ahead of print September 29, 2020]. Clin Infect Dis.

      Linked Article